Researchers continue to investigate: Triple hormone agonists Oral GLP-1 medications Combination therapies Muscle-preserving weight loss treatments These advancements are helping reshape the future of obesity medicine and may expand personalized treatment options for patients in the years ahead
Buyer Takeaway: Confirm the ingredient list from the physical product label
This data helps you maintain your rotation schedule and identify patterns if problems develop
Current Regulatory Status Retatrutide has not received Health Canada approval
NEJM 2023: 10.1056/NEJMoa2301972 Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity)
If youre someone struggling with diabetes, weight, or related conditions, GLP-1 might be worth exploring but ONLY and ONLY under expert guidance